Combination Therapy of an Antibody Specific for Transferrin Receptor 1 (ch128.1/IgG1) With Bortezomib or Lenalidomide Results in Increased Survival in an In Vivo Model of Human Multiple Myeloma: A Brief Communication.

Candelaria, Pierre V; Nava, Miguel; Martínez-Maza, Otoniel; Daniels-Wells, Tracy R; Penichet, Manuel L

Candelaria, Pierre V; Nava, Miguel; Martínez-Maza, Otoniel; Daniels-Wells, Tracy R; Penichet, Manuel L.

Afiliación

Candelaria PV; Division of Surgical Oncology, Department of Surgery.
Nava M; Division of Surgical Oncology, Department of Surgery.
Martínez-Maza O; Departments of Obstetrics and Gynecology.
Daniels-Wells TR; AIDS Institute.
Penichet ML; Department of Epidemiology, UCLA Fielding School of Public Health.

J Immunother ; 45(5): 227-230, 2022 06 01.

Article en En | MEDLINE | ID: mdl-35467582

Asunto(s)

Mieloma Múltiple; Animales; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico; Bortezomib/farmacología; Bortezomib/uso terapéutico; Comunicación; Dexametasona; Humanos; Inmunoglobulina G; Lenalidomida/uso terapéutico; Ratones; Ratones SCID; Receptores de Transferrina

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Mieloma Múltiple Límite: Animals / Humans Idioma: En Revista: J Immunother Asunto de la revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google